Did Biocardia beat or miss consensus estimates last quarter?

What factors drove the changes in Biocardia's revenue and profit?

What guidance did Biocardia's management provide for the next earnings period?

What is the revenue and EPS growth rate for Biocardia year over year?

What were the key takeaways from Biocardia’s earnings call?

What were the key takeaways from Biocardia's earnings call?

What is the market's earnings forecast for Biocardia next quarter?

What is Biocardia's gross profit margin?

- **Phase III Trial Success**: CardiAMP showed statistically significant reductions in left ventricular volumes (20 mL/m² and 15 mL/m²) in patients with elevated NT-proBNP, supporting subgroup targeting for FDA and PMDA submissions.
- **Upcoming Regulatory Milestones**: Q-Submission to FDA and clinical consultation with PMDA expected to drive 2026 approvals, with potential for a shorter De Novo pathway.
- **Financial Stability**: 2025 cash of $2.5 million and controlled expenses position BioCardia for continued clinical advancement with modest R&D growth in 2026.
- **Competitive Edge**: CardiAMP’s minimally invasive delivery and subgroup-focused data differentiate it from surgical therapies, positioning it as a leading cell therapy for heart failure.

**【CEO Summary Section】**
- BioCardia’s lead program, CardiAMP autologous cell therapy, showed significant reductions in left ventricular volumes in a phase III trial, particularly in patients with elevated biomarkers of heart stress (NT-proBNP). The trial demonstrated a 20 mL/m² reduction in end-systolic volume (p=0.02) and 15 mL/m² reduction in end-diastolic volume (p=0.01) in this subgroup.
- The company plans to submit a Q-Submission to the FDA for approvability of CardiAMP for ischemic heart failure, with a focus on the subgroup with elevated biomarkers. A formal clinical consultation with Japan’s PMDA is also scheduled.
- Four key upcoming catalysts include: FDA Q-Submission, PMDA consultation, FDA feedback on the Helix delivery system, and an oral presentation at EuroPCR on chronic myocardial ischemia (CMI) data.
- Enrollment in the confirmatory CardiAMP HF II trial has begun at four sites, with potential to transition to a post-marketing registry if FDA approves an earlier pathway.

**【CFO Financial Commentary】**
- Total expenses for 2025 increased 3% to $8.3 million, driven by a 13% rise in R&D ($5 million) due to clinical trial closeout activities and regulatory efforts. SG&A decreased 10% to $3.3 million due to lower professional fees.
- Net loss was $8.2 million, with cash of $2.5 million at year-end. 2026 guidance includes modest R&D growth and stable SG&A, with continued focus on cash management.

**【Q&A Key Highlights】**
- **Echo Data Significance**: CEO emphasized that while full cohort P-values (0.06/0.09) were near significance, subgroup data (p=0.02/0.01) strongly support targeting patients with elevated NT-proBNP for regulatory approval. This aligns with PMDA’s interest in subgroup analysis.
- **Competitive Position**: CardiAMP’s minimally invasive delivery and cost-effectiveness differentiate it from surgically delivered allogeneic therapies. CEO expects CardiAMP to remain a leading therapy due to robust clinical data and ease of use.
- **Enrollment Strategy**: Enrollment in HF II is prioritizing regulatory clarity before scaling, with potential to leverage trial data for enrollment momentum post-approval discussions.

Biocardia Inc (BCDA) Q4 2025 Earnings Call Transcript

- **Clinical Milestones**: CardiAmp HF II trial enrolling at four centers; Japan PMDA consultations and FDA meeting in Q4 2025. BCDA02 CMI data shows 80-second exercise improvement in five patients.
- **Financial Stability**: $5.3 million cash runway to Q2 2026; no immediate funding needs. R&D expenses up 0.5% YoY due to trial expansion.
- **Regulatory Focus**: Helix system FDA submission Q4 2025; potential Japan approvals for CardiAmp HF and allogeneic stem cells.
- **Partnerships & Innovation**: Heart 3D fusion imaging with CARTech for enhanced delivery; NIH funding for BCDA03 trial.

**【CEO Summary Section】**
- **CardiAmp Cell Therapy Progress**: FDA breakthrough designation for ischemic heart failure; three clinical trials show promise. PMDA consultations in Japan for potential approval, with FDA meeting planned for Q4 2025.
- **CardiAmp HF II Trial**: 250-patient phase III trial enrolling at four centers, using advanced cell analysis for dosing. Medicare reimbursement for all patients. Long-term follow-up data positive, with no safety issues.
- **BCDA02 (Chronic Myocardial Ischemia)**: Open-label rolling cohort of five patients shows 80-second increase in exercise tolerance and 82% reduction in angina episodes. Results being prepared for publication.
- **BCDA03 (Allogeneic Stem Cells)**: Phase I-II trial with 39 patients; seeking NIH funding for completion, expected in Q1 2026. Potential conditional approval in Japan.
- **Helix Delivery System**: FDA 510(k) submission planned for Q4 2025. Integration with heart 3D fusion imaging for enhanced delivery.

**【CFO Financial Commentary】**
- **Q3 2025 Financials**: R&D expenses $936,000 (up 0.5% YoY) due to HF II trial and regulatory activities. SG&A $0.6 million (down 25% YoY) from lower compensation. Net loss $1.5 million, cash $5.3 million, providing runway to Q2 2026.
- **Cash Position**: $6 million from September financing and ATM sales. No immediate need for additional funding.

**【Q&A Highlights】**
- **CMI Data Clarity**: Five-patient rolling cohort shows significant improvement; trial design includes Hawthorne effect mitigation (1-month observation period).
- **Enrollment Challenges**: Resource constraints and site startup costs; no safety or efficacy hurdles. Enrollment expected to accelerate post-regulatory clarity.
- **Japan and FDA Strategy**: PMDA consultations focus on existing data sufficiency. FDA meeting to discuss approvability based on phase II/III results.
- **Funding for BCDA03**: High probability of NIH grant in Q1 2026, enabling trial completion without dilution.

BioCardia, Inc. (BCDA) Q3 2025 Earnings Call Transcript

- **Regulatory Momentum**: Q4 2025 meetings with PMDA and FDA for CardiAMP approval, with Japan's conditional pathway and U.S. confirmatory trial.
- **Trial Progress**: CardiAMP II enrolling at 5 sites, targeting open-label registry. Helix FDA review underway.
- **Financial Stability**: Q2 2025 cash $980K, ATM sales $769K, runway to October. R&D up 75% for regulatory efforts.
- **Strategic Partnerships**: Morph DNA and Helix discussions in Japan; CardiALLO non-dilutive funding expected.

**【CEO Summary Section】**
- Presented Q2 2025 CardiAMP Heart Failure trial results with a primary endpoint p-value of 0.17 and subgroup p-value of 0.02 for elevated NT-proBNP patients. Seeking regulatory meetings with Japan's PMDA and FDA in Q4 2025.
- CardiAMP Heart Failure II trial enrolling at 4 sites, soon expanding to 5. Helix biotherapeutic delivery system under FDA de novo 510(k) review.
- Non-dilutive funding for CardiALLO allogeneic stem cell therapy expected in Q1 2026. Active partnerships discussions for Morph DNA steerable introducer sheath in electrophysiology.

**【CFO Financial Commentary】**
- Q2 2025 R&D expenses $1.4M (75% YoY increase), SG&A $0.7M (stable). Net loss $2.0M, cash balance $980K after $769K ATM sales. Runway to October 2025.

**【Q&A Highlights】**
- Japan PMDA may approve CardiAMP with post-marketing studies; FDA may require confirmatory data. CardiAMP II aiming for open-label registry if approved. Helix partnerships in Japan for distribution. CardiALLO's cost efficiency attracting interest.

BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript

- **Clinical Milestone**: CardiAMP heart failure trial shows safety and efficacy in 200+ patients, positioning for FDA/Japan PMDA submissions.
- **Growth Catalysts**: 
  - CardiAMP HF II trial with 250-patient enrollment and enhanced dosing strategy.
  - Helix biotherapeutic delivery system nearing U.S. approval.
  - Japan market opportunity with 1 million+ addressable patients.
- **Financial Strength**: Controlled burn rate ($2.7M Q1 expenses) and $1.6M cash post-funding provide flexibility.
- **Partnership Potential**: Morph DNA platform discussions with large-cap medtech companies; CardiALLO open to non-cardiac indications.

**【CEO Summary Section】**
- **CardiAMP Heart Failure Trial Results**: Demonstrated safety and meaningful benefits for heart failure patients, with 1 million potential U.S. patients annually. FDA and Japan PMDA consultations are prioritized for regulatory alignment.
- **Clinical Trial Progress**: 
  - CardiAMP HF II trial enrolling at 3 sites, targeting 250 patients with enhanced enrollment strategies (e.g., pre-procedure screening assay for dosing adjustments).
  - BCDA-02 trial final data analysis underway for chronic myocardial ischemia.
  - BCDA-03 trial (allogeneic stem cell therapy) safety outcomes positive with no adverse events in low-dose cohort.
- **Partnership Strategy**: 
  - Helix biotherapeutic delivery system positioned for U.S. approval; discussions with therapeutic partners to leverage minimally invasive delivery advantages.
  - Morph DNA introducer platform advantages highlighted in complex cardiac procedures (e.g., ventricular arrhythmias).
  - Open to partnerships for CardiALLO allogeneic cell therapy in non-cardiac indications (e.g., acute respiratory distress).
- **Japan Market Focus**: PMDA submission for CardiAMP cell therapy expected soon; 200+ patient data set vs. peers' 8-10 patient trials in Japan. Medicare reimbursement in U.S. reduces trial costs.
- **Financial Position**: Small financing with minimal dilution; cash of $949K pre-funding, with controlled burn rate enabling flexibility.

**【CFO Financial Commentary】**
- **Q1 2025 Financials**: 
  - Total expenses: $2.7M (vs. $2.3M Q1 2024), driven by R&D ($1.5M vs. $1.2M) for trial closures and new enrollments.
  - Net loss: $2.7M (vs. $2.3M Q1 2024); cash used in operations: $1.6M (vs. $1.5M Q1 2024).
  - Cash balance: $949K pre-funding, with $1.6M raised post-quarter.
- **2025 Outlook**: Modest R&D increases for trial advancements; SG&A expected to track 2024 levels.

**【Q&A Key Takeaways】**
- **Business Development Maturity**: Multiple active discussions with large-cap strategics on Morph DNA and Helix platforms. CardiAMP HF II trial design changes (e.g., quality of life endpoint) aim to enhance power and reduce patient dropout.
- **Japan PMDA Submission**: Similar to FDA BLA acceptance; 6-month timeline for clarity. Potential valuation gap with peers (e.g., Heartseed: $350M market cap with 10 patients treated).
- **Tariff Policy Impact**: Minimal impact on BioCardia due to U.S.-based manufacturing focus. Pricing strategy focuses on value (e.g., $20K U.S. reimbursement vs. $124K Japan peer pricing).

BioCardia (BCDA)-14 May 25-2025 Q1 Earnings call transcript

- **Breakthrough Clinical Data**: CardiAMP cell therapy demonstrates 47% reduction in heart death equivalents and statistical significance in high-risk patients, positioning for regulatory approval.
- **Cost-Effective Growth**: 35% expense reduction in 2024 with $2.4M cash on hand, enabling strategic trials without financial strain.
- **Regulatory Momentum**: FDA and PMDA engaged on conditional approval pathways, with Japan PMDA prioritizing unmet need in heart failure.

**【CEO Clinical Trial Update】**
- **CardiAMP-HF Trial Results**: 115 patients showed a 47% relative risk reduction in heart death equivalents and 16% reduction in major adverse cardiac events. Quality of life improved by 10.5 points (p=0.14), and 6-minute walk distance increased by 13.9 meters. Patients with elevated NTproBNP (heart stress marker) achieved statistical significance (p=0.02) in composite endpoints.
- **CardiAMP-HF2 Trial**: Now activated with enhanced enrollment criteria, targeting patients with elevated NTproBNP. Expected to be overpowered based on Phase I data.
- **Regulatory Pathway**: FDA and PMDA consultations underway. Japan PMDA expressed interest in conditional approval due to unmet need in ischemic heart failure.

**【CFO Financial Overview】**
- **2024 Year-End Results**: Total expenses decreased 35% to $8.1M (from $12.1M in 2023), driven by 43% R&D reduction post-CardiAMP-HF trial completion. Net loss narrowed to $7.9M (from $11.6M). Cash balance of $2.4M with moderate 2025 cash burn expected.
- **Cost Efficiency**: SG&A expenses down 16% to $3.7M, reflecting operational streamlining.

**【Q&A Highlights】**
- **Japan PMDA Update**: BioCardia plans to submit 2-year data for consultation, targeting conditional approval. PMDA feedback indicates alignment with Phase I results.
- **Enrollment Momentum**: CardiAMP-HF2 sites in the U.S. and Canada ramping up. Europe activation under consideration.
- **Financial Sustainability**: 2025 R&D and SG&A expenses expected to remain stable, supporting clinical trial expansion.

Actual			-10.05	-6.9	-4.5	-0.75	-2.7	-3	-2.4	-3.15	-2.85	-2.1	-2.55	-2.55	-2.55	-2.55	-1.8	-1.35	-1.35	-0.88	-0.61	-0.06	-0.59	-0.4	-0.24	0
Forecast			-6.15	-2.1	-3.8625	-4.5	-3.3	-3.15	-3.15	-2.5125	-2.475	-3.72	-3.4125	-2.7	-2.4	-2.35	-1.8	-1.125	-3	-0.1	-1.19	-0.625		-0.5	-0.23	-0.17
Surprise	0.00%	0.00%	-63.41%	-228.57%	-16.50%	+83.33%	+18.18%	+4.76%	+23.81%	-25.37%	-15.15%	+43.55%	+25.27%	+5.56%	-6.25%	-8.51%	0.00%	-20.00%	+55.00%	-780.00%	+48.74%	+90.40%	0.00%	+20.00%	-4.35%	+100.00%

BCDA

BCDA fundamentals

BCDA Q4 2025 Earnings

Earnings Call

You can ask Aime

BCDA

BCDA fundamentals

BCDA Q4 2025 Earnings

Earnings Call

BCDA Earnings Call Summary for Q4/20254:30 PM on Mar 24, 2026

BCDA Earnings Call Summary for Q3/20254:30 PM on Nov 12, 2025

BCDA Earnings Call Summary for Q2/20254:30 PM on Aug 11, 2025

BCDA Earnings Call Summary for Q1/20254:30 PM on May 14, 2025

BCDA Earnings Call Summary for Q4/20244:30 PM on Mar 31, 2025

You can ask Aime